Date: 2015-01-19
Type of information: Collaboration agreement
Compound: proprietary technology to transport therapeutic antibodies into the brain
Company: Vect-Horus (France) Sanofi (France)
Therapeutic area: Neurodegenerative diseases
Type agreement: collaboration
Action mechanism: Transporting drugs across the blood-brain barrier is a technological barrier that Vect-Horus intends to lift, allowing thereby the treatment of neurodegenerative diseases, particularly with therapeutic antibodies. Vect-Horus designs and develops peptide-vectors that facilitate the delivery of drugs or imaging agents into organs, notably into the brain, and tumors. By combining these molecules of interest to peptide-vectors targeting specific membrane receptors, the company allows them to cross natural barriers (the first of which, the blood-brain barrier) that restrict access to their target territory: organ, tissue, brain, tumor...
Disease:
Details: * On January 19, 2015, Vect-Horus, a biotechnology company that designs and develops peptide-vectors that facilitate the delivery of drugs or imaging agents into organs, notably into the brain, and tumors, announced the signing of a scientific collaboration agreement with Sanofi. The goal of this collaboration is to use Vect-Horus’ proprietary technology to transport therapeutic antibodies into the brain for the treatment of a neurodegenerative disease. The agreement with Sanofi is part of Vect-Horus’ framework strategy, which is to use its proprietary technology to enter into R&D agreements with biopharmaceutical companies to generate
patentable new chemical entities, based on the vectorization of their drug candidates.
Financial terms:
Latest news:
